86% of pharma and biotech companies plan to invest in ‘digitally agile’ supply chains in the next 12 months
March 6, 2023Business Services
LONDON 6th March 2023 86% of pharma and biotech companies say they plan to become more digitally agile, according to …
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
March 3, 2023Business Services
Manchester, UK, 3rd March 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver …
Globesity: the silent pandemic of the 21st century. Multidisciplinary and new incisionless endoscopic technique may be an effective solution for adult patients.
March 3, 2023Business Services
London, 03/03/2023- Ahmed is 45 years old and weighed 120 kg. He was always very tired, and would even fall …
Elon Musk’s Neuralink rejected by FDA for human trials
March 3, 2023Medical Communications
The FDA has reportedly rejected a bid by Elon Musk’s Neuralink in which they proposed the initiation of human testing …
FDA grants orphan drug designation to Temferon for glioblastoma multiforme
March 3, 2023Medical Communications
The FDA has granted Temferon an Orphan Drug Designation (ODD) for use as a therapeutic option for patients with glioblastoma …
Eli Lilly signs $40m licensing deal with Confo Therapeutics over neuropathic pain treatment
March 3, 2023Sales and Marketing
US-based pharmaceutical company Eli Lilly has signed a small licensing deal with Belgian start-up Confo Therapeutics to allow them access …
A gene test could guide decisions around chemotherapy for bowel cancer
March 3, 2023Medical Communications
Scientists from the Institute of Cancer Research London, Imperial College London and the Netherlands Cancer Institute have researched a gene …
Positive Results from POLB 001 LPS Human Challenge Trial
March 2, 2023Business Services
Key Highlights
Sanofi and Sobi celebrate completion of XTEND-Kids phase 3 study
March 2, 2023Research and Development
A collaborative study between Sanofi and Sobi called XTEND-Kids phase 3 has finished, solidifying the first milestone needed for regulatory …
Microba Life Sciences launches next-generation healthcare testing for gastrointestinal health
March 2, 2023Medical Communications
Australian precision microbiome company Microba Life Sciences has launched its next-generation testing range for gastrointestinal health. MetaXplore has been relaunched …
Eli Lilly caps consumer insulin costs at $35
March 2, 2023Medical Communications
Eli Lilly & Co has announced that it will cap out-of-pocket insulin costs at $35 per month, following a plea …
FDA panel backs GSK RSV vaccine ahead of approval
March 2, 2023Medical Communications
Yesterday, GSK shared that an advisory committee from the FDA voted in support of its respiratory syncytial virus (RSV) vaccine …
Menopause Action Plan – How nutritional support can keep female employees at work
March 1, 2023Business Services
Through simple nutrition and lifestyle changes HR managers could enable women to continue to thrive at work and pursue their …
Ten new companies enter BioInnovation Institute’s Venture Lab program
March 1, 2023Business Services
COPENHAGEN, Denmark, March 1, 2023 – BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today …
Koa Health appoints Dr Anna Mandeville as UK Clinical Director and Leslie Norwalk to the Supervisory Board
March 1, 2023Business Services
London, 1st March 2023: Koa Health, a leading global provider of digital mental healthcare solutions, today announces that Dr Anna …
PureTech to Present at the Barclays Global Healthcare Conference
March 1, 2023Business Services
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment …
NICE recommends more digital mental health therapies for NHS use
March 1, 2023Medical Communications
Eight more digital therapies (DTx) for mental health disorders have been recommended by NICE for use by the NHS, following …
FDA approves Reata Pharmaceuticals’ first-in-class treatment for Friedreich’s Ataxia
March 1, 2023Medical Communications
US-based Reata Pharmaceuticals has announced that its first-in-class treatment for Friedreich’s Ataxia (FA), Skyclarys, has been given FDA approval. This …
BioNxt Solutions signs clinical study agreement and commences clinical samples manufacture for Parkinson’s disease trial
March 1, 2023Research and Development
BioNxt Solutions, a bioscience accelerator focused on next-generation drug formulations and delivery systems, has announced the finalisation of its comparative …
Sequana Medical shares positive results from phase 1 clinical trial
March 1, 2023Research and Development
Sequana Medical has shared positive results from its phase 1 trial, CHIHUAHUA, assessing the safety and tolerability of a single …
Latest content
FibroFind appoints Lee Borthwick as CEO
